Literature DB >> 20568588

Bisphosphonates: do we know their role in adjuvant breast cancer treatment?

Myra F Barginear1, Catherine Van Poznak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20568588      PMCID： PMC3050541     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  14 in total

1.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

Authors:  C L Shapiro; J Manola; M Leboff
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

2.  Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.

Authors:  Stephanie L Hines; Betty Anne Mincey; Jeff A Sloan; Sachdev P Thomas; Elaine Chottiner; Charles L Loprinzi; Mark D Carlson; Pamela J Atherton; Muhammad Salim; Edith A Perez
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

3.  Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.

Authors:  Janet E Brown; Susan P Ellis; James E Lester; Sandra Gutcher; Tina Khanna; Om-Prakesh Purohit; Eugene McCloskey; Robert E Coleman
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

4.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

5.  The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.

Authors:  Andrew Grey; Mark J Bolland; Diana Wattie; Anne Horne; Greg Gamble; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

6.  Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

Authors:  Adam M Brufsky; Linda D Bosserman; Richard R Caradonna; Barbara B Haley; C Michael Jones; Halle C F Moore; Lixian Jin; Ghulam M Warsi; Solveig G Ericson; Edith A Perez
Journal:  Clin Breast Cancer       Date:  2009-05       Impact factor: 3.225

7.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Authors:  Michael Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Franz Kainberger; Helmut Kässmann; Jutta Claudia Piswanger-Sölkner; Michael Seifert; Ferdinand Ploner; Christian Menzel; Peter Dubsky; Florian Fitzal; Vesna Bjelic-Radisic; Günther Steger; Richard Greil; Christian Marth; Ernst Kubista; Hellmut Samonigg; Peter Wohlmuth; Martina Mittlböck; Raimund Jakesz
Journal:  Lancet Oncol       Date:  2008-08-19       Impact factor: 41.316

Review 8.  Advances in adjuvant endocrine therapy for postmenopausal women.

Authors:  Nancy U Lin; Eric P Winer
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

9.  Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

Authors:  James E Lester; David Dodwell; Omprakash P Purohit; Sandra A Gutcher; Susan P Ellis; Ruth Thorpe; Janet M Horsman; Janet E Brown; Rosemary A Hannon; Robert E Coleman
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 10.  Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.

Authors:  Oliver Bock; Dieter Felsenberg
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458
View more
  1 in total

Review 1.  Direct antitumour activity of zoledronic acid: preclinical and clinical data.

Authors:  Joaquim Bosch-Barrera; Sofía D Merajver; Javier A Menéndez; Catherine Van Poznak
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.